Share Regeneron earnings beat forecasts as stronger Sanofi profits lift revenue
← Stock movers news
Earnings results
Regeneron Pharmaceuticals, Inc.REGN · Biotechnology
REGN · October 30, 2026Before open · Since the previous regular close
+7.15%Session snapshot

Regeneron earnings beat forecasts as stronger Sanofi profits lift revenue

Earnings results

  • EPS beat +22.2%

    Actual: $20.07 · Cons.: $16.42 (non-GAAP diluted EPS)

  • Revenue beat +12.2%

    Actual: $5.1158B · Cons.: $4.56B (reported total revenue)

  • Guidance

    2026 adjusted product gross margin raised to about 86% from 84%–85%; adjusted R&D spending raised to $6.05–$6.15B

550
Regeneron Pharmaceuticals building
Archive photograph of a Regeneron Pharmaceuticals building, January 2023; illustrative of the company’s business. Photo: ajay_suresh / Wikimedia Commons · CC BY 2.0 · Wikimedia-supplied thumbnail; displayed with a responsive crop.
THE CATALYST

Earnings and the stock move

The newly released earnings show improving partnership economics alongside commercial growth. Investors should separate durable medicine demand and a larger profit share from the upcoming upfront payment, which belongs to a later quarter.

AT A GLANCE

Q3 2026 ended September 30 earnings recap

Regeneron rose 7.1% pre-market on October 30, 2026 after earnings beat forecasts. Stronger Sanofi collaboration profits helped lift revenue.

  • Adjusted EPS, or profit per share excluding specified accounting items, reached $20.07 versus the $16.42 forecast. GAAP profit per share was $18.45.
  • Revenue reached $5.12 billion versus the $4.56 billion forecast, a 12.2% beat. The company earns both medicine sales and income from development partnerships.
  • Sanofi collaboration income benefited from stronger Dupixent demand and the end of repayments for earlier development costs. That improves Regeneron’s share of partnership economics.
  • Eylea HD sales in the U.S. rose 62% to $699 million, but combined sales with the older Eylea declined 1%. Competition remains a risk despite the newer treatment’s growth.
  • The expanded Sanofi agreement brings $1 billion upfront, to be recognized in the fourth quarter. Up to $7 billion of further payments depends on milestones; it is not guaranteed revenue.
  • The annual adjusted product gross-margin outlook rose to about 86% from 84%–85%. Higher research spending means part of the commercial improvement will fund future medicines.

Watch the next regular session for follow-through and whether product demand sustains the profit improvement. The charts end at the October 29 close, before these results; drug-development and pricing risks remain.

THE VISUAL RESEARCH

Financials and technicals

Charts through Oct 29, 2026. The session move above may reflect later news.

Financials
Technicals
WHAT TO WATCH

Technical setup and risks

The October 29 completed charts precede the earnings release. Holding above the prior $825–$830 high area would support the advance. Falling below the prior $797–$805 range would weaken the recovery; earnings can gap through chart levels.

AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.

EXPLORE COMPANY RESEARCH

Regeneron Pharmaceuticals: the full stock picture

Earnings history, financials, price action and peer comparisons — all below.
Open REGN stock page ↗

EXPLORE THE COMPANY

Regeneron Pharmaceuticals (REGN)

Explore earnings, price action, financials and industry comparisons.

Symbol
REGN
Sector
Healthcare
Industry
Biotechnology
Instrument type
EQUITY

Profile information from our saved company catalog. This is not a live quote or confirmation of current listing status.

EARNINGS & COMPANY RESEARCH

REGN earnings, valuation & price action

View in calendar ↗
NEXT EXPECTED REPORTJan 28 2027Time unconfirmed · ET
EPS ESTIMATE25.39
REVENUE ESTIMATE5.85B

Expected dates may change. Estimates use the source’s reporting currency. Quotes and research are snapshots, not live prices.

Loading REGN earnings research…

REGN earnings previews and market catalysts

October 30, 2026: Intel’s weak outlook hits technology shares as Mondelēz gains
2026-10-30 · Intel’s warning about weak PC demand weighs on technology shares before open. Mondelēz benefits from improving volumes and margins, while Gilead raises its sales outlook.

All upcoming earnings catalysts →

02 / FINANCIALS

Regeneron Pharmaceuticals financials

Revenue, earnings, cash flow and financial strength in one view.

Reporting currency unconfirmed.

Revenue
Net income
Gross profit
Operating income
EBITDA
Operating cash flow
Capital expenditure
Cash
Total assets
Total liabilities
Shareholder equity
Total debt
Net profit margin
Gross margin
Short interest: days to cover
How to read these financial metrics

Figures use the app’s saved statements for the displayed period, not a trailing-year total. Margins divide profit by revenue; quick ratio uses current assets less inventory divided by current liabilities. Compare dates and currencies before comparing companies.

03 / WHAT COMES NEXT

Regeneron Pharmaceuticals event catalysts

Company earnings and scheduled market events that may change expectations.

2027-01-28

REGN earnings

Watch reported results, management’s outlook and the share-price reaction.

See earnings expectations ↑
2026-11-108:30 AM ET

CPI inflation

Compare headline and core inflation with expectations; watch Treasury yields and growth stocks.

Release schedule ↗Scheduled
2026-11-11Time not announced

MSCI · index review announcement

Review official additions, deletions and weight changes; release time is not specified here.

Release schedule ↗Scheduled
2026-11-128:30 AM ET

Initial jobless claims

Use the multiweek trend to distinguish normal volatility from a sustained increase in layoffs.

Release schedule ↗Scheduled
2026-11-138:30 AM ET

PPI inflation

Watch the surprise versus expectations and implications for margins and interest rates.

Release schedule ↗Scheduled
2026-11-13Time not announced

Russell · preliminary additions/deletions

Check the official lists. Preliminary changes can be revised.

Release schedule ↗Scheduled
2026-11-16Filing deadline · ET date

13F filing deadline · Q3 holdings

Filings may arrive earlier and positions can have changed. A filing is not a new trade or a guarantee of buying pressure.

Release schedule ↗Scheduled
2026-11-178:30 AM ET

Retail sales

Look beyond autos and gasoline; stronger spending can help earnings but also keep yields elevated.

Release schedule ↗Scheduled
2026-11-179:15 AM ET

Industrial production

Check factory output and utilization for changes in cyclical demand.

Release schedule ↗Scheduled

Dates use U.S. Eastern time and can change. Calendar events provide context; they do not determine the direction of a stock move.

04 / SIDE BY SIDE

Compare REGN with its peers

Industry · Compare valuation, financial strength and price performance.

Companies with valuation data0
Peer median positive P/E
REGN P/E
REGN peer comparison: valuation
CompanyPriceMarket capP/EForward P/EP/SForward P/S
REGNRegeneron Pharmaceuticals

The peer median excludes the selected stock and is based on 0 available positive multiples. P/E median excludes negative or missing earnings multiples. Peer reports can have different fiscal periods and currencies; values are not currency-converted.

05 / PEER ANALYSIS

Explore REGN alongside its peers

Biotechnology · 45 companies · Cached market data

Comparison

Compare companies

Tap a bubble to inspect a company, then × to hide it. Undo restores the last company hidden. Bubble area reflects market cap, with a minimum size for visibility.

Price / sales
0.0×0138.5×51.89B277.0×103.78B415.5×155.67BVRTX · Vertex Pharmaceuticalsorpor Market cap: 139.16B Price / sales: 10.7×MRNA · Moderna Market cap: 91.2B Price / sales: 40.9×ALNY · Alnylam Pharmaceuticals Market cap: 21.57B Price / sales: 4.3×BNTX · BioNTech Market cap: 21.29B Price / sales: 7.9×BBIO · BridgeBio Pharma Market cap: 15.17B Price / sales: 16.0×BMRN · BioMarin Pharmaceutical Market cap: 10.86B Price / sales: 3.0×IONS · Ionis Pharmaceuticals Market cap: 6.68B Price / sales: 7.6×CRSP · CRISPR Therapeutics AG Market cap: 4.97B Price / sales: 371.3×BEAM · Beam Therapeutics Market cap: 2.87B Price / sales: 19.6×NVAX · Novavax Market cap: 1.61B Price / sales: 3.9×Market cap
REGNRegeneron Pharmaceuticals

Market cap: 78.17B
Price / sales:

Valuation snapshot: See app
10 of 45 companies have both plotted values.

P/S distribution

Trailing price-to-sales multiples · 10 companies

Median P/S9.3×
Middle 50%5.1× to 18.7×
REGN P/S
2.7×20.6×

Tap a bar to see the companies in that P/S range.

35 companies excluded from P/S statistics because sales are non-positive or the saved multiple is missing. Statistics include all valid positive values, including those outside the focused chart range.

Companies

Showing 8 of 45 matching companies · Largest market cap first

  • Market cap 139.16BP/E 35.1×P/S 10.7×Forward P/E Forward P/S Price snapshot: 2026-11-09
    ↗
  • Market cap 91.2BP/E P/S 40.9×Forward P/E Forward P/S Price snapshot: 2026-11-09
    ↗
  • Market cap 78.17BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 51.98BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 25.34BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 24.07BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 24.01BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 21.57BP/E 7.9×P/S 4.3×Forward P/E Forward P/S Price snapshot: 2026-11-09
    ↗

Explore industries

Open an industry for its comparison, valuation and companies.

U.S.-listed companies from the app’s catalog. Medians use saved positive P/E values; coverage and snapshot dates vary.

How this comparison works

Uses the saved companies from the same industry and listing market, including REGN, ordered by cached market cap. Company snapshots can have different dates; the web cache may cover fewer metrics and periods than the app.

Periods end at each company’s dated price snapshot. Change compares the latest saved observation with one at or before the selected period’s start. A daily price change uses consecutive saved sessions. Financial data updates quarterly, so short periods may show no change. Missing history and zero starting values are excluded; a negative starting value uses its absolute value as the denominator.

Metrics use saved ratios and percentages. Market caps use the listing market’s reporting currency; underlying financial statements may use different currencies. Circle sizes have a minimum for touch visibility, and an outlined circle indicates a missing market cap. These comparisons describe data, not recommendations or price predictions.

INDUSTRY COMPARISON

REGN industry peers

Biotechnology · Oct 16, 2026 · Closing-price performance

Compare REGN with 1 other stock in the available heatmap coverage.